CDNA vs TXMD

For growth investors, TherapeuticsMD, Inc.

(TXMD) is the stronger pick with 35. 3% revenue growth year-over-year, versus 13. 8% for CareDx, Inc (CDNA). Analysts rate CareDx, Inc (CDNA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CareDx, Inc (CDNA) delivered a total return of -72.

4%, compared to -96. 3% for TherapeuticsMD, Inc. (TXMD). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus TXMD's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TherapeuticsMD, Inc.

(TXMD) is the lower-risk stock at 0. 51β versus CareDx, Inc's 1. 39β — meaning CDNA is approximately 171% more volatile than TXMD relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 26% for TherapeuticsMD, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TherapeuticsMD, Inc.

(TXMD) is pulling ahead at 35. 3% versus 13. 8% for CareDx, Inc (CDNA). On earnings-per-share growth, the picture is similar: TherapeuticsMD, Inc. grew EPS 74. 3% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, CDNA leads at 5. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CareDx, Inc (CDNA) is the more profitable company, earning -5.

6% net margin versus -123. 9% for TherapeuticsMD, Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNA leads at -5. 5% versus -270. 3% for TXMD. At the gross margin level — before operating expenses — TXMD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TherapeuticsMD, Inc.

(TXMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51)). Both have compounded well over 10 years (TXMD: -99. 5%, CDNA: +385. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CDNA is a small-cap quality compounder stock; TXMD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.